Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Using ADHD Medications to Treat Coexisting ADHD and Reading Disorders: A Systematic Review.

Froehlich TE, Fogler J, Barbaresi WJ, Elsayed NA, Evans SW, Chan E.

Clin Pharmacol Ther. 2018 Oct;104(4):619-637. doi: 10.1002/cpt.1192. Epub 2018 Aug 30.

PMID:
30053315
2.

The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder.

Storebø OJ, Faltinsen E, Zwi M, Simonsen E, Gluud C.

Clin Pharmacol Ther. 2018 Oct;104(4):606-609. doi: 10.1002/cpt.1149. Epub 2018 Jul 13.

PMID:
30006934
3.

Getting to Long-Term Effectiveness and Safety of Attention-deficit Hyperactivity Disorder Medications.

Beau-Lejdstrom R, Zito JM.

Clin Pharmacol Ther. 2018 Oct;104(4):610-612. doi: 10.1002/cpt.1137. Epub 2018 Aug 17.

PMID:
30120774
4.

Treating a Child With Mental Illness.

Ito S.

Clin Pharmacol Ther. 2018 Oct;104(4):592-594. doi: 10.1002/cpt.1182.

PMID:
30222188
5.

MR imaging of the effects of methylphenidate on brain structure and function in attention-deficit/hyperactivity disorder.

Schweren LJ, de Zeeuw P, Durston S.

Eur Neuropsychopharmacol. 2013 Oct;23(10):1151-64. doi: 10.1016/j.euroneuro.2012.10.014. Epub 2012 Nov 17. Review.

PMID:
23165220
6.

Early life exposure to air pollution particulate matter (PM) as risk factor for attention deficit/hyperactivity disorder (ADHD): Need for novel strategies for mechanisms and causalities.

Myhre O, Låg M, Villanger GD, Oftedal B, Øvrevik J, Holme JA, Aase H, Paulsen RE, Bal-Price A, Dirven H.

Toxicol Appl Pharmacol. 2018 Sep 1;354:196-214. doi: 10.1016/j.taap.2018.03.015. Epub 2018 Mar 14. Review.

PMID:
29550511
7.

Medications used in the treatment of disruptive behavior in children with FASD--a guide.

Ozsarfati J, Koren G.

J Popul Ther Clin Pharmacol. 2015;22(1):e59-67. Epub 2015 Feb 12. Review.

PMID:
25715382
8.
9.

Methylphenidate improves reading performance in children with attention deficit hyperactivity disorder and comorbid dyslexia: an unblinded clinical trial.

Keulers EH, Hendriksen JG, Feron FJ, Wassenberg R, Wuisman-Frerker MG, Jolles J, Vles JS.

Eur J Paediatr Neurol. 2007 Jan;11(1):21-8. Epub 2006 Dec 13.

PMID:
17169593
10.

The beneficial effect of methylphenidate in ADHD with comorbid separation anxiety.

Golubchik P, Golubchik L, Sever JM, Weizman A.

Int Clin Psychopharmacol. 2014 Sep;29(5):274-8. doi: 10.1097/YIC.0000000000000034.

PMID:
24743562
11.

Reading outcomes of children and adolescents with attention-deficit/hyperactivity disorder and dyslexia following atomoxetine treatment.

Shaywitz BA, Williams DW, Fox BK, Wietecha LA.

J Child Adolesc Psychopharmacol. 2014 Oct;24(8):419-25. doi: 10.1089/cap.2013.0148. Epub 2014 Oct 9.

PMID:
25299355
12.

European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.

Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L.

Eur Neuropsychopharmacol. 2013 Oct;23(10):1208-18. doi: 10.1016/j.euroneuro.2012.11.012. Epub 2013 Jan 15.

13.

Comorbidity of ADHD and dyslexia.

Germanò E, Gagliano A, Curatolo P.

Dev Neuropsychol. 2010;35(5):475-93. doi: 10.1080/87565641.2010.494748. Review.

PMID:
20721770
14.

The effect of methylphenidate-OROS<sup>®</sup> on the narrative ability of children with attention-deficit hyperactivity disorder.

Rausch TL, Kendall DL, Kover ST, Louw EM, Zsilavecz UL, Van der Merwe A.

S Afr J Commun Disord. 2017 Feb 27;64(1):e1-e12. doi: 10.4102/sajcd.v64i1.180.

15.

Methylphenidate treatment in children with attention deficit hyperactivity disorder and comorbid social phobia.

Golubchik P, Sever J, Weizman A.

Int Clin Psychopharmacol. 2014 Jul;29(4):212-5. doi: 10.1097/YIC.0000000000000029.

16.

Aggregated n-of-1 trials of central nervous system stimulants versus placebo for paediatric traumatic brain injury--a pilot study.

Nikles CJ, McKinlay L, Mitchell GK, Carmont SA, Senior HE, Waugh MC, Epps A, Schluter PJ, Lloyd OT.

Trials. 2014 Feb 13;15:54. doi: 10.1186/1745-6215-15-54.

17.

[Pharmacological treatment of dyslexia].

Artigas-Pallarés J.

Rev Neurol. 2009 Jun 1-15;48(11):585-91. Spanish.

18.
19.

Might stimulant drugs support moral agency in ADHD children?

Hyman SE.

J Med Ethics. 2013 Jun;39(6):369-70; discussion 372-3. doi: 10.1136/medethics-2012-100846. Epub 2012 Sep 21.

20.

Attention deficit/hyperactivity disorder across the lifespan.

Wilens TE, Biederman J, Spencer TJ.

Annu Rev Med. 2002;53:113-31. Review.

PMID:
11818466

Supplemental Content

Support Center